Enjoy complimentary customisation on priority with our Enterprise License!
The fallopian tube cancer therapeutics market size is estimated to grow by USD 832.01 million at a CAGR of 10.35% between 2023 and 2028.
Fallopian tube cancer therapeutics market Share
For More Highlights About this Report, Download Free Sample in a Minute
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Growing attention toward women's health is the key factor driving market growth. The market encountered a challenge with the absence of understanding about various gynecologic cancer indications, such as fallopian tube cancer and ovarian cancer. Thus, different organizations and governments across the globe are working on increasing awareness to overcome certain challenges associated with the diagnosis and treatment of fallopian tube cancer.
Additionally for clinical targeting, fallopian tube cancer has witnessed significant growth due to a multitude of recent drug approvals, particularly in the realm of chemotherapy. Traditionally, chemotherapy stood as the primary therapeutic approach for fallopian tube cancer treatment. The advancements in targeted therapies, alongside the established role of chemotherapy, have significantly broadened the scope of available treatments for fallopian tube cancer patients.
The advent of treatment vaccines for cancer is the primary trend shaping market growth. Vaccines are therapeutics that are issued to increase the body's immune response against a particular pathogen or a disease-causing gene. For a long time, the global pharmaceuticals market only had preventive vaccines. However, the advances in the healthcare infrastructure have resulted in the advent of treatment vaccines, which have the ability to treat a certain indication after its progression
In addition, the cancer treatment vaccines that are currently being developed for fallopian tube cancer are made from cancer-specific antigens; however, research is also being conducted on the development of personalized cancer treatment vaccines, in which the vaccine is produced from the patient tumor sample. Nowadays, multiple cancer treatment vaccines are being developed in the late stages of clinical trials for fallopian tube cancer. Thus, such factors will drive the growth of the market during the forecast period.
Difficulty in diagnosis of fallopian tube cancer is a challenge that affects market growth. Due to fallopian tube cancer's close relation to other gynecologic cancers, the diagnosis of fallopian tube cancer is favourably complex, as the signs are very similar to other indications. Furthermore, the complicated pathogenesis of the indication is also stopping the market from overcoming the challenge associated with the high mortality rate concerning its survival rate of the indication.
The survival rates for fallopian tube cancer vary based on several factors, including the stage at diagnosis, the extent of tumor spread, the type of trial received, and individual patient characteristics and immunotherapy.
Moreover, the market does not witness any research being conducted on new-age trials methods for the indication.However, chemotherapy limitations, including side effects and its inability to provide sustained relief, prompted pharmaceutical companies to explore alternative avenues. This exploration led to the development of novel targeted therapies designed to specifically inhibit certain overexpressed targets in cancerous cells and bolster the body's immunity against them through immunotherapy.
As a result, the difficulty in diagnosis of the indication is expected to pose a significant threat to the growth of the global fallopian tube cancer therapeutics market during the forecast period.
The market share growth by the hospitals segment will be significant during the forecast period.The hospitals segment was valued at USD 565.70 million in 2018. Hospitals, the largest providers of cancer treatment, make up 66% of healthcare companies that are planning to change their entire business model. Hospital pharmacies constantly juggle cutting costs and staying within budget due to the high inbound costs of oncology medications.These factors are expected to augment the demand for fallopian tube cancer therapeutics through the hospital pharmacies segment, which will thus drive the growth of the hospitals segment of the global fallopian tube cancer therapeutics market during the forecast period
Get a glance at the market contribution of various segments Download the PDF Sample
Product Segment - Targeted Therapy
The Ovarian cancer drug market is segmented as Targeted therapy drugs and chemotherapy.Targeted therapy drugs have the ability to suppress the activity of a specific cell, protein, or gene that is causing cancer. These drugs target the changes in cancer cells that are responsible for the cancer cells growth, division, and spreading. Targeted therapies can either be small molecule-based drugs or biologics, such as monoclonal antibodies. Small molecule-based drugs are highly effective in inhibiting cell growth by entering the cancer cells, and monoclonal antibody-based targeted therapies attach to a specific target that is found on a cancer cell, thereby inhibiting its ability to spread. Targeted therapies have the ability to mark the cancer cells, thereby triggering an immune response to kill the cell. They are also known to increase the immunity of the body against cancer cells while inhibiting their growth
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Chemotherapy in the Treatment of Fallopian Tube Cancer
The fallopian tube cancer therapeutics market in North America is poised for substantial growth, driven by the increasing adoption of therapeutics for this indication. Chemotherapy is a treatment method that utilizes powerful radiation and drugs to destroy or slow down the growth of cancer cells. Radiation therapy may also be utilized in certain cases to target and destroy cancer cells in the fallopian tubes.
Fallopian tube cancer, chemotherapy is often a primary or adjunct treatment option. Chemotherapy is often recommended as an adjuvant or neoadjuvant therapy for fallopian tube may be used before surgery. Chemotherapy is often recommended as an adjuvant or neoadjuvant therapy for the fallopian tube to shrink the tumour, making it easier to remove, or after surgery to target and eliminate any remaining cancer cells and reduce the risk of recurrence.
Initially, surgery and chemotherapy were the primary treatments, but with limited efficacy and high side effects, there was a significant unmet need. Vendors have responded by developing targeted therapies like VEGF and PARP inhibitors, gaining FDA approval.
For instance, Pafolacianine received FDA approval in November 2021 for treating advanced ovarian cancer. The advanced healthcare infrastructure in North America attracts vendors for clinical trials, resulting in a robust pipeline with late-stage molecules. Government initiatives promoting women's health awareness are expected to increase the incidence of fallopian tube cancer. Although PARP and VEGF inhibitors exhibit high efficacy, their adoption is hindered by high costs. To address this, vendors have launched patient assistance programs, such as Roche's Genentech BioOncology Co-pay Card and AstraZeneca's Access 360 program. These programs aim to overcome cost barriers and promote the adoption of therapeutics for fallopian tube cancer during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Baxter International Inc.: The company offers fallopian tube cancer therapeutics such as DOXIL which is used to treat ovarian cancer and kaposi sarcoma.
Immunogen Inc- The company offers fallopian tube cancer therapeutics such as ZEJULA which is used as treatment for women with advanced ovarian cancer after responding to platinum based chemotherapy.
Johnson and Johnson -The company offers fallopian tube cancer therapeutics such as ZEJULA which is used as treatment for women with advanced ovarian cancer after responding to platinum based chemotherapy.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
|
Fallopian Tube Cancer Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
169 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.35% |
|
Market growth 2024-2028 |
USD 832.01 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.01 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Amgen Inc., Arrien Pharmaceuticals LLC, AstraZeneca Plc, Baxter International Inc., BioVaxys Technology Corp., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Clinigen Group Plc, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ImmunoGen Inc., Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Siemens Healthineers AG, Sun Pharmaceutical Industries Ltd., and Clovis Oncology Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
